Foster Dykema Cabot & Co’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
$497K Buy
3,332
+83
+3% +$12.2K 0.06% 56
2023
Q2
$438K Sell
3,249
-32
-1% -$4.69K 0.05% 60
2023
Q1
$523K Buy
3,281
+250
+8% +$38.2K 0.07% 56
2022
Q4
$490K Sell
3,031
-410
-12% -$62.9K 0.07% 51
2022
Q3
$462K Hold
3,441
0.06% 56
2022
Q2
$527K Sell
3,441
-80
-2% -$12.2K 0.07% 52
2022
Q1
$571K Sell
3,521
-155
-4% -$22.5K 0.07% 58
2021
Q4
$498K Hold
3,676
0.06% 66
2021
Q3
$397K Sell
3,676
-304
-8% -$34.7K 0.05% 72
2021
Q2
$448K Sell
3,980
-418
-10% -$47.1K 0.06% 66
2021
Q1
$476K Sell
4,398
-322
-7% -$34.4K 0.06% 62
2020
Q4
$506K Sell
4,720
-1,044
-18% -$100K 0.07% 65
2020
Q3
$505K Sell
5,764
-106
-2% -$9.98K 0.08% 63
2020
Q2
$576K Buy
5,870
+68
+1% +$5.99K 0.1% 57
2020
Q1
$442K Hold
5,802
0.09% 54
2019
Q4
$514K Hold
5,802
0.07% 68
2019
Q3
$439K Hold
5,802
0.06% 77
2019
Q2
$422K Sell
5,802
-26
-0.4% -$2.04K 0.06% 78
2019
Q1
$470K Sell
5,828
-135
-2% -$11K 0.08% 71
2018
Q4
$550K Hold
5,963
0.1% 59
2018
Q3
$564K Sell
5,963
-27
-0.5% -$2.56K 0.09% 65
2018
Q2
$548K Sell
5,990
-52
-0.9% -$5.08K 0.09% 66
2018
Q1
$572K Hold
6,042
0.1% 68
2017
Q4
$584K Sell
6,042
-410
-6% -$38.6K 0.1% 67
2017
Q3
$573K Hold
6,452
0.1% 62
2017
Q2
$468K Sell
6,452
-360
-5% -$24.2K 0.08% 76
2017
Q1
$444K Hold
6,812
0.08% 76
2016
Q4
$427K Hold
6,812
0.08% 77
2016
Q3
$430K Sell
6,812
-720
-10% -$46.6K 0.09% 79
2016
Q2
$466K Sell
7,532
-680
-8% -$41.4K 0.11% 69
2016
Q1
$469K Hold
8,212
0.11% 63
2015
Q4
$486K Buy
+8,212
New +$473K 0.12% 63
2015
Q3
Sell
-3,277
Closed -$220K 88
2015
Q2
$220K Buy
+3,277
New +$214K 0.06% 84
2015
Q1
Sell
-3,277
Closed -$214K 89
2014
Q4
$214K Buy
+3,277
New +$207K 0.05% 88
2013
Q4
Sell
-12,025
Closed -$538K 92
2013
Q3
$538K Sell
12,025
-610
-5% -$27K 0.16% 53
2013
Q2
$522K Buy
+12,635
New +$553K 0.16% 54

Other funds holding ABBV

Foster Dykema Cabot & Co's ABBV Position: Q3 2023 in Review

Foster Dykema Cabot & Co increased its AbbVie (ABBV) stake by 2.6% in Q3 2023, buying an estimated $12.2K and bringing the position to 3,332 shares worth $497K. The position accounts for 0.06% of the portfolio, ranked #56.

Foster Dykema Cabot & Co first reported a position in ABBV in Q2 2013 and has held it in 36 quarters since. The position peaked at $584K in Q4 2017. 3,108 funds tracked by Wall St. Rank hold ABBV as of Q3 2023.

  • Foster Dykema Cabot & Co held 3,332 shares of AbbVie worth $497K as of Q3 2023.
  • Foster Dykema Cabot & Co bought 83 AbbVie shares in Q3 2023, an estimated $12.2K.
  • AbbVie made up 0.06% of Foster Dykema Cabot & Co's portfolio in Q3 2023, its #56 holding.
  • Foster Dykema Cabot & Co first reported a position in AbbVie in Q2 2013 and has held it in 36 quarters since.
  • Foster Dykema Cabot & Co's AbbVie position peaked at $584K in Q4 2017.
  • 3,108 funds tracked by Wall St. Rank held AbbVie as of Q3 2023.

Based on Foster Dykema Cabot & Co's 13F filing for Q3 2023, filed 14 Nov 2023.